Literature DB >> 22586166

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease.

Serdal Ugurlu, Didar Ucar, Emire Seyahi, Gulen Hatemi, Sebahattin Yurdakul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22586166     DOI： 10.1136/annrheumdis-2012-201383

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  27 in total

1.  Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study.

Authors:  Giacomo Emmi; Rosaria Talarico; Giuseppe Lopalco; Rolando Cimaz; Fabrizio Cantini; Ombretta Viapiana; Ignazio Olivieri; Matteo Goldoni; Antonio Vitale; Elena Silvestri; Domenico Prisco; Giovanni Lapadula; Mauro Galeazzi; Florenzo Iannone; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2015-07-10       Impact factor: 2.980

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 3.  The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.

Authors:  Melissa A Lerman; C Egla Rabinovich
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 4.  Evasion of inflammasome activation by microbial pathogens.

Authors:  Tyler K Ulland; Polly J Ferguson; Fayyaz S Sutterwala
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 5.  Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Authors:  Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Bruno Frediani; Rossella Franceschini; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Claudia Fabiani; Luca Cantarini
Journal:  Rheumatol Int       Date:  2017-07-27       Impact factor: 2.631

6.  [Update: Behçet's disease].

Authors:  I Kötter
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

Review 7.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

8.  Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Authors:  Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Lorenzo Vannozzi; Silvana Guerriero; Stefano Gentileschi; Daniela Bacherini; Rossella Franceschini; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-12-16       Impact factor: 2.980

Review 9.  Pediatric Behçet's disease - clinical aspects and current concepts.

Authors:  Mehmet Yıldız; Oya Köker; Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Eur J Rheumatol       Date:  2019-09-05

10.  Canakinumab treatment in children with familial Mediterranean fever: report from a single center.

Authors:  Fatma Yazılıtaş; Özlem Aydoğ; Sare Gülfem Özlü; Evrim Kargın Çakıcı; Tülin Güngör; Fehime Kara Eroğlu; Gökçe Gür; Mehmet Bülbül
Journal:  Rheumatol Int       Date:  2018-02-15       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.